Abstract: PUB101
Hyperkalaemia Prevalence, Recurrence, and Treatment in Haemodialysis: A Prospective Multicentre Cohort Study (PRECEDE-K Trial)
Session Information
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Ni, Zhaohui, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
- Jin, Haijiao, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
- Lu, Renhua, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
- Zuo, Li, Peking University People’s Hospital, Beijing, China
- Yu, Weimin, Shanxi Bethune Hospital, Taiyuan, China
- Wang, Junsheng, Suqian People’s Hospital of Nanjing Drum-Tower Hospital Group, Suqian, China
- Wang, Rong, Shandong Provincial Hospital, Jinan, China
- Ren, Yuqing, Yangquan Coal Industry (Group) General Hospital, Yangquan, China
- Yang, Qiongqiong, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
- Xiao, Jie, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Zhang, Qinghong, Taihe Hospital of Shiyan City, Shiyan, China
- Zhang, Lihong, The First Hospital of Hebei Medical University, Shijiazhuang, China
- Zhang, Xinzhou, Shenzhen People’s Hospital, Shenzhen, China
- Chen, Qinkai, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Chen, Chaosheng, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- Shao, Guojian, Wenzhou Central Hospital, Wenzhou, China
- Luo, Qun, Ningbo No.2 Hospital, Ningbo, China
- Yao, Li, The First Hospital of China Medical University, Shenyang, China
- Qin, Shuguang, Guangzhou First People's Hospital, Guangzhou, China
- Peng, Hui, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- Zhao, Qing, AstraZeneca Investment China Co Ltd, Shanghai, China
- Shang, Hongyan, AstraZeneca Investment China Co Ltd, Shanghai, China
Group or Team Name
- The PRECEDE-K study group
Background
Hyperkalaemia (HK) is a potentially life-threatening electrolyte imbalance associated with several adverse clinical outcomes and is common in patients with kidney failure. However, there is no evidence on the occurrence, recurrence, and treatment of HK in patients on haemodialysis (HD) in China.
Methods
The HK Prevalence, Recurrence, and Treatment in Haemodialysis Trial (PRECEDE-K; NCT04799067) is a prospective, multicentre, observational cohort study being conducted across 18 sites in China. Approximately 600 patients with end-stage kidney disease on HD are anticipated to be enrolled and will be followed up with for 24 weeks. Patients will be in the long interdialytic interval (LIDI) at enrolment and will receive follow-up care every four weeks in LIDI for pre-dialysis and post-dialysis (at enrolment only) serum potassium measurements. To obtain pre-dialysis serum potassium levels in the short interdialytic interval (SIDI), a follow-up visit in SIDI in Week 1 will be performed. Concomitant medications, blood gas analysis, and biochemistry measurements will be obtained at enrolment and at each follow-up visit.
Results
The primary endpoint is the proportion of patients experiencing any HK (defined as serum potassium > 5.0 mmol/L) at the study enrolment or during a 24-week follow-up. The key secondary endpoint is the proportion of patients experiencing HK recurrence (defined as any HK event after the first HK event) within 1–6 months (if applicable) during a 24-week follow-up, including enrolment assessment.
Conclusion
PRECEDE-K will generate high-quality evidence on the occurrence, recurrence, and treatment pattern of HK in patients on HD in China, and is expected to help inform practice guidance for HK management.
Funding
- Commercial Support – AstraZeneca